Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06920043
PHASE2

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

Sponsor: GlaxoSmithKline

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

Official title: A Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

42

Start Date

2025-04-09

Completion Date

2028-07-10

Last Updated

2026-07-08

Healthy Volunteers

No

Interventions

DRUG

Efimosfermin

Efimosfermin will be administered as a subcutaneous injection.

DRUG

Placebo

Placebo will be administered as a subcutaneous injection.

Locations (30)

GSK Investigational Site

Chandler, Arizona, United States

GSK Investigational Site

Mesa, Arizona, United States

GSK Investigational Site

Tucson, Arizona, United States

GSK Investigational Site

Fresno, California, United States

GSK Investigational Site

Lancaster, California, United States

GSK Investigational Site

Pasadena, California, United States

GSK Investigational Site

Rialto, California, United States

GSK Investigational Site

Santa Maria, California, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Viera, Florida, United States

GSK Investigational Site

Marietta, Georgia, United States

GSK Investigational Site

Baltimore, Maryland, United States

GSK Investigational Site

Kansas City, Missouri, United States

GSK Investigational Site

New York, New York, United States

GSK Investigational Site

Fayetteville, North Carolina, United States

GSK Investigational Site

Wilson, North Carolina, United States

GSK Investigational Site

Austin, Texas, United States

GSK Investigational Site

Austin, Texas, United States

GSK Investigational Site

Austin, Texas, United States

GSK Investigational Site

Dallas, Texas, United States

GSK Investigational Site

Georgetown, Texas, United States

GSK Investigational Site

Houston, Texas, United States

GSK Investigational Site

Houston, Texas, United States

GSK Investigational Site

Houston, Texas, United States

GSK Investigational Site

Pasadena, Texas, United States

GSK Investigational Site

Pearland, Texas, United States

GSK Investigational Site

San Antonio, Texas, United States

GSK Investigational Site

San Antonio, Texas, United States

GSK Investigational Site

Waco, Texas, United States

GSK Investigational Site

Richmond, Virginia, United States